Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
As the aging population in the US, UK and Europe increases, cases of multiple have increased as well, bring new therapies and questions about the future of care. This webinar provides a comprehensive look at the disease and treatments including the new launches that are transforming clinical practice, the relative value of multiple myeloma regimens, and the evolution of the multiple myeloma market.
Beginning with the current access levers used by payers and a comparison of US and five major European markets, you’ll learn the key factors in European payers’ assessment of multiple myeloma treatments, the significant changes we are seeing in the US oncology market, and why payers have begun imposing cost-control strategies such as ICER and other value frameworks to evaluate cost-effectiveness.
Datamonitor Healthcare: data analysis and insight, Biomedtra...
As the biopharma industry concludes its annual pilgrimage to San Francisco for the JP Morgan investor conference, much of the talk around town inevitably was about gene therapies.
Topics Cell and gene therapy
Datamonitor Healthcare: data analysis and insight, Biomedtra...
Commentators at the ISPOR Europe 2019 conference in Copenhagen debated the challenges that exist with valuing and financing potentially curative treatments, including cell and gene therapies, and cancer immunotherapies. With several recent regulatory approvals of high-cost advanced therapy medicinal products (ATMPs), discussion has ensued in earnest on how to determine their clinical value, and whether traditional reimbursement and health technology assessment (HTA) processes are sufficient to assess these innovative treatments.
Datamonitor Healthcare: data analysis and insight
By Joseph Haas
Non-alcoholic steatohepatitis (NASH) is poised to become an even greater epidemic and pharma companies of all sizes are competing to be the first to bring a NASH drug to market. Listen to an in-depth discussion about new and repurposed drug exploration treat NASH, as well as deal making, licensing and partnerships activity for the area.
Topics Cell and gene therapy Drug Development Landscape Drug approval
Request a Trial
Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.
How can we help you?
Our team is always happy to hear from you. Please call us at:
Pharma Report Store
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now:
Trialtrove is the go-to resource for clinical trial research. Easily track your competitors' clinical R&D activity with expert insights and continually monitored trials.
Biomedtracker provides real-time analysis of major market-moving events in the pharma and biotech industries. With catalyst tracking and expert insights, you stay on top of breaking events, what’s in the drugs pipeline, upcoming milestones, clinical trial results and their impact on the markets you care about
Understand what’s happening in the market right now and what it means for the future of your business with news and insight from our team of journalists and analysts. Scrip is essential for anyone making commercial decisions in the pharmaceutical industry.
Looking for more products Product Finder
